<DOC>
	<DOCNO>NCT01779882</DOCNO>
	<brief_summary>The aim study test hypothesis , order application Busulfan ( BU ) Cyclophosphamide ( CY ) impact toxicity allogeneic Hematopoietic stem cell transplantation ( HSCT ) CY-BU reduce liver toxicity compare BU-CY .</brief_summary>
	<brief_title>Cyclophosphamide Busulfan Conditioning Regimen Before Allogeneic HSCT</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients plan undergo allogeneic HSCT myeloablative conditioning Age 18 65 year Myeloid leukemia respectively related precursor neoplasm ( acute myeloid leukemia , chronic myeloid leukemia , myelodysplastic syndrome ) , lymphoid neoplasm ( acute lymphoblastic leukemia/lymphoma , mature B/T/natural killer ( NK ) cell neoplasms ) . Human Leukocyte Antigen ( HLA ) identical sibling donor match unrelated ( min . 10/10 Ag match ) Patients history hepatitis might include , contraindication HSCT exist . Patient must give write informed consent Indication myeloid leukemia respectively related precursor neoplasm , lymphoid neoplasm . Severe liver damage &gt; 2 week ( bilirubin &gt; 3xupper limit normal ( ULN ) ASAT/ALAT &gt; 5xULN ) HIV infection Donor HLAidentical sibling min . 10/10 match unrelated donor Pregnant lactate woman Lack write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>